The Innovation Fund Denmark awards a DKK 5.8m grant to Notify Therapeutics
Notify Therapeutics, receives a Grand Solutions grant of DKK5.8m from the Innovation Fund Denmark. The aim of the grant is to fund the testing of Notify Therapeutic’s compound NTY001 in non-human primates to show the effect of NTY001 on egg maturation and embryo formation.
Infertility affects 48 million couples and 186 million individuals globally. Approximately ten percent of infertile women suffer from low ovarian reserves and for this reason do not benefit from currently available hormonal fertility treatment regimens. Their only option of getting pregnant is by use of donor eggs.
Through targeting of the early and hormone-independent phase of egg maturation, Notify Therapeutics works at developing a first-in-class treatment, which will help infertile women to become pregnant. The company focuses on the activation of so-called dormant follicles – a process that is pivotal for the generation of fertile eggs. This early phase of follicle development is fundamentally different from the later part of the follicel develoment, which is hormone-dependent. In March 2023, Notify Therapeutics received a grant of DKK 5.8m from the Innovation Fund Denmark to fund further in vivo studies in non-human primates, through the Grand Solutions Program. The Grand Solutions program invests in ambitious, cross-cutting research and innovation projects that can create new, concrete solutions to important politically prioritized societal challenges that create value to Denmark.
“We are extremely proud to receive a Grand solution sand this provides funding for us to test NTY001 in a translational animal model for mono-ovulatory species, resembling human reproduction and enables us to prepare for the clinicial study of NTY001 to benefit infertile patients,” says Karin Lykke-Hartmann, CEO and founder of Notify Therapeutics,and professor in Reproductive Medicine at the Department of BIomedicine, Aarhus University, Denmark.
For further information, please visit www.notifytherapeutics.com or contact Karin Lykke-Hartmann, founder, CEO of Notify Therapeutics, and professor in reproductive medicine at Aarhus University, Denmark.
Mail: karin@notifytherapeutics.com
About Notify Therapeutics
Notify Therapeutics is developing a first-in-class treatment for infertile women who benefit from having more mature eggs. Notify focuses on the initial ovarian follicle development to help infertile women, not benefitting from today’s standard hormone treatment. The company is developing a drug that regulates the intracellular AKT pathway; a major driver of follicle activation and a signal transduction pathway that promotes survival and growth in response to extracellular signals.
About Innovation Fund Denmark
Innovation Fund Denmark invests in entrepreneurs, researchers and businesses that create value for Denmark and new solutions to our society’s biggest challenges - and supports the development of new knowledge and technology creating growth and employment in Denmark.